Sinopharm FY2025 net profit rose 3.94% to RMB 10,834 million as net cash from operating activities climbed 22.45% to RMB 14,138 million

Reuters

昨天

Sinopharm FY2025 net profit rose 3.94% to RMB 10,834 million as net cash from operating activities climbed 22.45% to RMB 14,138 million

Sinopharm published a 2025 annual results presentation reporting business revenue of RMB575.17 billion, up 1.62%.
Net profits were RMB10.83 billion, up 3.94%, while net profits attributable to owners of the parent were RMB7.16 billion, up 1.5%.
Gross profit margin was 7.25% (down 0.32 percentage points) and net profit margin was 1.88% (up 0.1 percentage points).
Segment revenue included pharmaceutical distribution of RMB435.39 billion (up 2.06%) and medical device distribution of RMB115.54 billion (down 2.02%).
Retail pharmacy revenue was RMB38.38 billion (up 6.67%) and management said wholesale-retail integration and a dual-brand strategy supported growth, while it managed lower-efficiency device businesses with long payment terms to reduce risk.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2621403507"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621403507\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621403507?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 08:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621403507","market":"nz","top_or_hot":-1,"title":"Sinopharm FY2025 net profit rose 3.94% to RMB 10,834 million as net cash from operating activities climbed 22.45% to RMB 14,138 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sinopharm FY2025 net profit rose 3.94% to RMB 10,834 million as net cash from operating activities climbed 22.45% to RMB 14,138 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Sinopharm published a 2025 annual results presentation reporting business revenue of RMB575.17 billion, up 1.62%.\n        </li>\n<li>\n          Net profits were RMB10.83 billion, up 3.94%, while net profits attributable to owners of the parent were RMB7.16 billion, up 1.5%.\n        </li>\n<li>\n          Gross profit margin was 7.25% (down 0.32 percentage points) and net profit margin was 1.88% (up 0.1 percentage points).\n        </li>\n<li>\n          Segment revenue included pharmaceutical distribution of RMB435.39 billion (up 2.06%) and medical device distribution of RMB115.54 billion (down 2.02%).\n        </li>\n<li>\n          Retail pharmacy revenue was RMB38.38 billion (up 6.67%) and management said wholesale-retail integration and a dual-brand strategy supported growth, while it managed lower-efficiency device businesses with long payment terms to reduce risk.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SHTDF\">Sinopharm Group Co. Ltd.</a> published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sinopharm FY2025 net profit rose 3.94% to RMB 10,834 million as net cash from operating activities climbed 22.45% to RMB 14,138 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinopharm FY2025 net profit rose 3.94% to RMB 10,834 million as net cash from operating activities climbed 22.45% to RMB 14,138 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-23 08:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sinopharm FY2025 net profit rose 3.94% to RMB 10,834 million as net cash from operating activities climbed 22.45% to RMB 14,138 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Sinopharm published a 2025 annual results presentation reporting business revenue of RMB575.17 billion, up 1.62%.\n        </li>\n<li>\n          Net profits were RMB10.83 billion, up 3.94%, while net profits attributable to owners of the parent were RMB7.16 billion, up 1.5%.\n        </li>\n<li>\n          Gross profit margin was 7.25% (down 0.32 percentage points) and net profit margin was 1.88% (up 0.1 percentage points).\n        </li>\n<li>\n          Segment revenue included pharmaceutical distribution of RMB435.39 billion (up 2.06%) and medical device distribution of RMB115.54 billion (down 2.02%).\n        </li>\n<li>\n          Retail pharmacy revenue was RMB38.38 billion (up 6.67%) and management said wholesale-retail integration and a dual-brand strategy supported growth, while it managed lower-efficiency device businesses with long payment terms to reduce risk.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SHTDF\">Sinopharm Group Co. Ltd.</a> published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1197","symbol_name":"保健护理产品经销商","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL5kWYpj:1","article_id":"2621403507","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621403507","pubTimestamp":1774227097,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sinopharm FY2025 net profit rose 3.94% to RMB 10,834 million as net cash from operating activities climbed 22.45% to RMB 14,138 million. Sinopharm published a 2025 annual results presentation reporting business revenue of RMB575.17 billion, up 1.62%.Net profits were RMB10.83 billion, up 3.94%, while net profits attributable to owners of the parent were RMB7.16 billion, up 1.5%.Gross profit margin was 7.25%  and net profit margin was 1.88% .Segment revenue included pharmaceutical distribution of RMB435.39 billion  and medical device distribution of RMB115.54 billion .Retail pharmacy revenue was RMB38.38 billion  and management said wholesale-retail integration and a dual-brand strategy supported growth, while it managed lower-efficiency device businesses with long payment terms to reduce risk.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1197":"保健护理产品经销商","01099":"国药控股","LU0640798160.USD":"EASTSPRING INVESTMENTS GLOBAL EMERGING MARKET DYNAMIC \"A\" (USD) ACC","BK1515":"抗疫概念","BK1500":"做空集合股","LU1115378108.SGD":"Eastspring Investments - Global Emerging Markets Dynamic AS SGD"},"translate_title":"国药控股2025财年净利润增长3.94%至人民币108.34亿元，经营活动净现金增长22.45%至人民币141.38亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01099":0.9},"content_text":"Sinopharm FY2025 net profit rose 3.94% to RMB 10,834 million as net cash from operating activities climbed 22.45% to RMB 14,138 million\n    \n\n\n          Sinopharm published a 2025 annual results presentation reporting business revenue of RMB575.17 billion, up 1.62%.\n        \n\n          Net profits were RMB10.83 billion, up 3.94%, while net profits attributable to owners of the parent were RMB7.16 billion, up 1.5%.\n        \n\n          Gross profit margin was 7.25% (down 0.32 percentage points) and net profit margin was 1.88% (up 0.1 percentage points).\n        \n\n          Segment revenue included pharmaceutical distribution of RMB435.39 billion (up 2.06%) and medical device distribution of RMB115.54 billion (down 2.02%).\n        \n\n          Retail pharmacy revenue was RMB38.38 billion (up 6.67%) and management said wholesale-retail integration and a dual-brand strategy supported growth, while it managed lower-efficiency device businesses with long payment terms to reduce risk.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}